CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 42 enrolled
Drug / intervention
Interferon beta-1a +1 moredrug
Likely dose
Interferon beta-1a 22 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01075763
NCT01075763Phase 2Completed
CompareCT.gov

Pilot Trial of Interferon Beta-1a in Alzheimer's Disease

Merck KGaA, Darmstadt, Germany·interventional·Posted Feb 25, 2010·Updated Feb 13, 2014

In Brief

A Phase 2 clinical trial evaluating Interferon beta-1a and Placebo for Alzheimer's Disease. Completed, enrolled 42 participants across 1 site.

Detailed Summary

This was a 52-week, multicentric, phase II, pilot study conducted in 40 subjects with early-onset Alzheimer's disease (AD) to evaluate safety, tolerability and clinical efficacy of subcutaneous (sc) interferon (IFN) beta-1a \[Rebif® 22 microgram (mcg), three times per week (tiw)\] in the treatment of AD by comparing the neuropsychological performance changes into placebo and treatment arms from screening/baseline to 52 week.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesItaly
CollaboratorsMerck Serono S.P.A., Italy

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 25, 2010
Enrollment StartNov 1, 2004
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 16.4 years ago

Interventions

Interferon beta-1adrug

Interferon (IFN) beta-1a \[Rebif® 22 microgram (mcg), three times per week (tiw)\] administered subcutaneously (sc)

Placebodrug

The inactive substance (placebo) looks the same as Interferon beta-1a (Rebif®), and is given the same way